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Abstract 
Background. The extent of patient contact with medical services prior to development of 
community acquired AKI is unknown.  
Aims. We examined the relationship between incident community acquired electronic AKI 
alerts (CA-AKI), previous contact with hospital or primary care and clinical outcomes.   
Design. A prospective national cohort study of all electronic AKIalerts representing adult 
CA-AKI. 
Methods. Data was collected for all cases of adult (≥18yrs of age) CA-AKI in Wales 
between 1
st
 November 2013 and 31
st
 January 2017.   
Results. There were a total of 50560 incident CA-AKI alerts. In 46.8% there was a 
measurement of renal function in the 30 days prior to the AKI alert.   In this group, in 63.8% 
this was in a hospital setting, of which 37.6% were as an inpatient and 37.5% in A&E.  
Progression of AKI to a higher AKI stage (13.1% vs. 9.8%, p<0.001) (or for AKI 3 an 
increase of ≥50% from the creatinine value generating the alert), the proportion of patients 
admitted to Intensive Care (5.5% vs. 4.9%, p=0.001) and 90-day mortality (27.2% vs. 18.5%, 
p<0.001) was significantly higher for patients with a recent test.  90-day mortality was 
highest for patients with a recent test taken in an inpatient setting prior to CA-AKI (30.9%).   
Conclusion. Almost half of all patients presenting with CA-AKI are already known to 
medical services, the majority of which have had recent measurement of renal function in a 
hospital setting, suggesting that AKI for at least some of these may potentially be predictable 
and/or avoidable.   
  
Introduction 
Acute kidney injury (AKI) is a common health problem worldwide, affecting up to 1% of the 
general population and 15% of all hospitalised patients (1-3).  Severe AKI requiring dialysis 
is associated with a high rate of in-hospital mortality (4).  Less severe degrees of renal injury 
have also been associated with a significantly heightened risk of death, prolonged in-patient 
hospital stay and increased costs (5, 6).  AKI may also have long-lasting detrimental effects 
on a patient’s health, with an increased incidence of subsequent Chronic Kidney Disease 
(CKD) and mortality (7-10).   
AKI may occur during hospitalisation (HA-AKI), may be present at the time of admission to 
hospital or may occur and be managed in the community.  To date the majority of published 
studies contributing to our understanding of epidemiology and outcome of AKI, are based on 
AKI in hospitalised patients (11-13).  Amongst hospitalised patients the incidence of 
community acquired AKI (CA-AKI) is roughly twice that of hospital acquired AKI (14).   In 
contrast to HA-AKI much less is known regarding the nature and impact of CA-AKI of 
which 30-40% is not hospitalised (15, 16), AKI within primary care and the interface 
between primary and secondary care.  Up to half of all AKI detected by an electronic AKI 
alert based on a change in creatinine criteria, is accounted for by CA-AKI (15) of which only 
30% is detected in primary care (17).  In this manuscript we have examined the relationship 
between incident electronic CA-AKI alerts and previous contact with either hospital services 
or primary care and related this to the clinical course/outcome of an AKI episode.  Our aim 
was to highlight potential “predictable” AKI and possible missed opportunities to minimise 
the risk and impact of AKI.   
 
Methods 
Setting: Data was collected across the National Health Service in Wales which serves a 
population of 3.06 million. The study was approved under “Service Evaluation Project 
Registration”.  The previously described (and validated) Welsh electronic AKI reporting 
system (15, 18), utilises the Welsh Laboratory Information Management System (LIMS) 
(InterSystems TrakCare Lab) to automatically compare in real time measured creatinine 
values on an individual patient against previous results, to generate electronic alerts using an 
nationally agreed algorithm based on KDIGO AKI criteria (Supplementary Figure 1) (19).  
Three “rules” are applied to generate alerts differing in the time period from which the 
baseline creatinine is obtained. Rule 1 alerts represent a >26µmol/l increase in SCr within the 
previous 48 hours and are issued only if rule 2 and rule 3 are not satisfied. Rule 2 alerts 
represent a ≥50% increase in SCr within the previous 7 days, and a rule 3 alert represents a 
≥50% increase in SCr from the median of results from the previous 8 to 365 days.  
Data Collection: Data was collected for all cases of adult (≥18yrs of age) CA-AKI in Wales 
between 1
st
 November 2013 and the 31
st
 January 2017.  Clinical location, patient age, AKI 
stage and the rule under which the AKI alert was generated was collected together with all 
measurements of renal function for up to 30 days following the AKI alert. To prevent 
inclusion of known patients receiving renal replacement therapy, alerts transmitted by 
patients from a renal, renal transplant, or dialysis setting, and by patients who had a previous 
blood test in a dialysis unit were excluded.  
Mortality data were collected from the Welsh Demographic Service (WDS).  
Data analysis: CA-AKI was classified as any patients with an e-alert generated in a non-in-
patient setting. We defined an incident episode of AKI as 30 days, i.e. any AKI e-alert for the 
same patient within 30 days of a previous alert was not considered a new episode. The 
Medical Record Number (MRN) was used as the patient identifier. This is a unique reference 
number allocated to each patient registered in the National Laboratory Information 
Management System (LIMS) and allows for multiple visits/blood test requests across all 
locations in Wales to be linked. 
Patients were classified into two groups; those with a measurement of renal function within 
the preceding 30 days of the incident AKI alert (Recent test), and those without (No recent 
test). Alerts for the latter group were all therefore generated by a baseline creatinine value 
derived from the median of results from the last 30 to 365 days. 
Progression of AKI was defined as a peak AKI stage higher than that associated with incident 
e-alert or for stage 3 alerts an increase ≥50% from the Serum Creatinine value (SCr) 
generating the alert. Critical care admission was also used as a surrogate marker for disease 
severity, and was defined as a measurement of renal function in an Intensive Care (ICU) 
setting during the 30 day AKI episode. Pre-existing chronic kidney disease (PeCKD) was 
defined as an eGFR (calculated by CKDEpi eGFR formula (20)) <60ml/min/1.73m
2
 derived 
from the baseline SCr.   
Statistical analysis was carried out using SPSS software, version 20 (SPSS, Inc., Chicago, IL). 
Student’s t test and ANOVA were used for analysis of normally distributed data. Categorical 
data were compared using a Pearson chi-squared test. P values less than 0.05 were considered 
statistically significant differences. 
 
Results 
Over the study period there were a total of 50560 incident CA-AKI alerts.  The demographic 
data on the cohort is shown in table 1.   
CA-AKI and measurement of renal function in preceding 30 days.   
Characteristics of patients with a recent measurement of renal function (Recent test) and 
those without a recent measurement of renal function (No recent test) are shown in table 1.  
46.8% (23658) of all CA-AKI had a measurement of renal function during the 30-day period 
prior to the AKI alert.  The cohort of “Recent test” patients at the time of the incident alert, 
were significantly older (70.3±16.4yrs vs. 68.9±18.5yrs, p<0.001), had a higher proportion of 
male patients (48.2% vs. 42.8%, p<0.001), a higher proportion of pre-existing CKD (37.9%% 
vs. 30.9%, p<0.001), and a higher proportion of AKI 1 vs. AKI2/3 (recent test; AKI1 75%   
vs. no recent test; AKI173.2%, p<0.001).   
In this cohort of those with a previous measurement prior to the AKI episode, 63.8% of 
measurements were taken in a hospital setting (15096 of 23658), of which 37.6% were 
performed as an in-patient (n=5677, mean time since previous test 10.7±9.6days), 37.5% in 
an Accident and Emergency (A&E) setting (n=5667, mean time since previous test 7.3±8.8 
days) and 16.6% in an outpatient setting (n=2512, mean time since previous test 13.5±9.6 
days).  Only 30.8% of tests prior to the AKI episode in the “recent test” cohort were 
performed in primary care (7285 of 23658).  The mean time since the previous result in 
primary care was 13.3±9.7 days.  
Pre-existing CKD prior to the AKI episode was highest in those with previous test results 
generated in primary care (46.9%) followed by patients with a result generated in A&E 
(33.6%) and patients with a test of renal function in an in-patient setting (31.5%, p<0.001 for 
all comparisons).  In contrast the highest proportion of AKI1 was seen in patients previously 
monitored in A&E (78.8%) followed by primary care (75.5%) and an in-patient setting 
(73.2%, P<0.001 for all comparisons).  
 
Clinical setting of AKI detection 
The clinical location of AKI alerts is shown in Table 3. For the cohort of patients with no 
recent test a higher proportion of AKI was detected in primary care (38.4% vs. 23.5%, 
P<0.001) and less at A&E (48.3% vs. 55.7%, p<0.001), than those with a recent test.   
Within the recent test cohort, an A&E presentation with the incident AKI episode was 
significantly more likely for patients with previous A&E testing prior to the AKI alert 
(81.0%) compared to previous in-patient testing prior to the AKI alert (60.2%, p<0001) 
which was significantly greater than for primary care tested patients (47.9%, p<0.001).   
In contrast presentation to primary care with the incident AKI episode was significantly 
greater for patients with previous primary care testing (43.2%) compared to previous in-
patient testing (19.2%, p<0.001), which was significantly greater than for patients previously 
tested at A&E (10.3%, p<0.001).  
 
Response to and Impact of AKI 
The clinical location of the blood test immediately following the AKI alert is shown in Table 
4. Patients who did not have a test result in the 30 days prior to the incident AKI alert were  
less likely to have a repeat blood test after the incident AKI alert than those known to medical 
services previously (81.0% vs. 88.9%, p<0.001).  For those who did have a repeat blood test 
following the incident AKI episode the time to repeat was significantly shorter for the known 
cohort (known 6.4±12.0days vs. 10.2±17.3days p<0.001), this relationship was consistent for 
the groups in which the repeat blood test was undertaken in Primary care (known 
12.4±14.2days vs. 17.6±19.3days p<0.001), A&E (known 6.4±12.3days vs. 7.5±16.5days 
p<0.001) or in an in-patient setting (known 2.3±5.5days vs. 3.1±8.3days, p<0.001).  
A higher proportion of those not known, following the incident AKI episode remain in 
primary care for subsequent blood tests (24.2% vs. 16.5%, p<0.001), and a lower proportion 
are admitted as an in-patient to hospital (29.9% vs. 36.1%, p<0.001) than those who were 
known to medical services.  
In the patients with a blood test prior to the AKI alert either in A&E or in an in-patient setting 
a higher proportion were likely to be seen in hospital (either at A&E or as an in-patient) for 
retesting of renal function following an AKI alert than those in whose previous measurement 
of renal function was undertaken in primary care (69.2% vs. 50.1% p<0.001), in which a 
higher proportion had renal function re-measured in primary care following the alert (30.2% 
vs. 10.4%, p<0.001).   
Overall 90-day mortality for CA-AKI was 22.6%. Progression of AKI to a higher AKI stage 
(or for AKI 3 an increase ≥50% from the SCr generating the alert) was greater in the cohort 
of patients previously known to medical services (13.1% vs. 9.8%, p<0.001). The proportion 
of patient admitted to Intensive Care was also higher in this group (5.5% vs. 4.9%, p=0.001).  
In addition 90-day mortality was also significantly higher for patients already “known” to 
medical services compared to those with no blood test in the  30-days prior to the AKI alert 
(27.2% vs. 18.5%, p<0.001).  In the cohort of “known” patients at the time of the incident 
alert (i.e. a blood test within 30 days), mortality was higher in those seen prior to the AKI 
episode as an in-patient (30.9%) than either those seen prior in Primary care (26.9%, p<0.001 
vs. in-patient) or seen previously at A&E (26.8%, p<0.001 vs. in-patient).  
 
Discussion 
Despite advances in health care, the incidence of AKI is increasing both in the UK (21, 22) 
and USA (23, 24).  Potential explanations for this increase may be related to increasingly 
aggressive medical and surgical therapies in a largely aging population with multiple 
comorbid conditions (25).  The significance of AKI is highlighted by the increase in mortality 
associated with even small changes in serum creatinine (26-28).  In contrast to HA-AKI less 
is known regarding CA-AKI although it is clear that CA-AKI is a major contributor to the 
overall disease burden (13, 29).  In this manuscript we provide a novel insight into the nature 
and outcome of CA-AKI and the patient journey in the days and weeks prior to and 
immediately following the detection of AKI.  
 
The first notable finding in this study is that almost half of the patients who generated a CA-
AKI alert have a measurement of renal function in the 30 days preceding the alert. For the 
majority of these patients this measurement was undertaken within two weeks of the incident 
AKI episode.  As might be expected this group was older and had a higher proportion of 
CKD suggesting that this is a group with higher co-morbidity and therefore AKI risk factors.  
In keeping with this, mortality was also higher in patients which were known to medical 
services prior to development of AKI, at least as judged by a recent test of renal function.  Of 
those with a recent test, for more than half, the review and measurement of renal function had 
been undertaken in a hospital setting. Although labelled as CA-AKI, given the short time 
frame between test and AKI incident alert it is possible that the incident AKI episode was 
related to either the illness precipitating the consultation or change made in response to the 
presenting symptoms.   It is interesting therefore to speculate that within this group that AKI 
is some cases at least was predictable and therefore potentially avoidable.  Within the group 
with a “recent test” the highest mortality was seen in patients who had a measurement of 
renal function in an inpatient setting within roughly a fortnight of the AKI episode.  This was 
also the group with the highest incidence of de-novo AKI (i.e. the lowest proportion of pre-
existing CKD).  The lower mortality in patients monitored in primary care prior to the AKI 
episode reflects the highest proportion of acute on chronic AKI, whilst the lower mortality in 
those with a measurement of renal function at A&E prior to the AKI episode reflect less 
severe AKI at presentation which may also reflect the shortest time interval between the 
previous measured renal function and the AKI episode suggesting early presentation.   
 
Whilst this study highlights a large cohort of patients who develop AKI following recent 
hospital attendance, a weakness is its dependence of an e-alert system which lacks clinical 
context.  Further work is therefore required to understand the relationship between medical 
service interactions/interventions, patient inter-current illness and their contribution to the 
development of CA-AKI, to identify any intervention or patient related risk factors which in 
particular might highlight who among the recent hospital attendees might be at risk and 
potentially benefit from early clinical review.  Recent data however, derived from a cohort of 
patients with HA-AKI have identified five clusters of diagnoses to be associated with 
development of AKI: sepsis, heart disease, poly-trauma, liver disease and cardiovascular 
surgery (30).  This suggests that patients recently discharged back to the community 
following hospital attendance for these indications may benefit from early clinical review to 
facilitate early detection, prompt re-assessment of patients, close monitoring of patient 
physiology, review of medication or consideration of hospitalisation in an attempt to improve 
patient outcomes.   
 
Whilst presentation to A&E is the most common presentation for CA-AKI, for those without 
a recent test the likelihood of presentation to primary care with the incident episode of AKI 
was higher.  For patients in whom renal function was recently measured the site of 
presentation with the incident AKI episode also reflected where the previous blood test was 
undertaken, such that a previous recent blood test in A&E predicted presentation to A&E 
with the incident AKI episode and similarly a recent blood test in primary care predicted 
those who presented to primary care with the AKI episode.  This suggests that patients when 
acutely unwell are most likely to return to a “familiar” port of call for health advice.  Our data 
also suggest that patients who have had recent measurement of renal function are more likely 
to have a repeat measurement following an AKI alert and that the time to a repeat blood test 
for this group is also significantly shorter.  It is likely that this reflects both patient as well as 
medical staff related behavioural factors. The place of detection of AKI also influences the 
likelihood of hospital admission with AKI detected in primary care generating the lowest 
number of admissions.  This is consistent with our previous data on AKI in primary care 
which demonstrated that admission from primary care was associated with AKI severity (17).  
Whilst admission was associated with higher mortality it was of note that in surviving 
patients non-admission was associated with worse renal outcomes, and that patients who 
were not hospitalized had a lower rate of renal recovery and a greater likelihood of 
developing an eGFR <60ml/min/1.73m
2
 for the first time, which may be indicative of 
development of de novo CKD (15).  This is also consistent with the recent report of Sawheny 
in which non-admitted AKI whilst having a lower mortality was associated with greater non-
recovery of renal function (31).  Previous data suggest that “non-admission” is at least in part 
is due to lack of recognition of the significance of the alert (14-16).  Furthermore, we have 
demonstrated that a delayed response to the alert in primary care is associated with a 
significantly worse renal outcome (17). Based on these observations we have previously 
recommended that a clinical review or referral together with a repeat measurement of renal 
function within 7 days should be considered an appropriate response to AKI e-alerts in 
primary care. 
 
In conclusion this study demonstrates that almost half of all patients presenting with CA-AKI 
are already known to medical services, suggesting that AKI for at least some of these may be 
potentially predictable and/or avoidable. Of these almost two thirds have a recent interaction 
with hospital either as an inpatient or via an A&E visit, thus suggesting that a sizable 
proportion of what is currently labelled as community acquired AKI may in fact relate to 
recent “hospitalisation” and may not actually be “community acquired”.  The challenge is to 
identify the group of patients in whom AKI may be predictable and for whom early clinical 
review is likely to reduce the incidence of or alter the outcome following AKI.   
 
Acknowledgements 
The work was carried out under the auspices of the Welsh AKI steering group which is 
sponsored by the Welsh Renal Clinical Network and Welsh Government 
Disclosures; There are no competing interests 
 
Supplementary Figure Legend 
 
Supplementary Figure 1: Algorithm for generating e-alerts for Acute Kidney Injury based on 
serum creatinine (SCr) changes with time.  RV, Reference value, defined as the SCr value 
with which the index SCr value is compared; D, difference between current and lowest 
previous result within 48 hours; RI, Population reference interval. 
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1	
	
Table	1:	Comparison	of	CA-AKI	patients	with	a	measurement	of	renal	function	within	the	preceding	30	days	of	an	alert	(Recent	test)	vs.	those	without	a	
measurement	of	renal	function	within	the	preceding	30	days	of	an	alert	(No	recent	test)	
	 	 	 	 	 ‘Recent	test’	cohort	
Variable	
All		
CA-AKI	 No	recent	test	 Recent	test	
P	value	
(Recent	test	
vs.	No	recent	
test)	
Previous	test	in	
primary	care	(PC)	
Previous	test	as	
an	inpatient	(IP)	
Previous	test	at	
A&E	(AE)	
P	value	(‘Recent	test’	
groups)	
Number	of	episodes	 50560	 26902	 23658	 	 7285	 5677	 5667	 	
Mean	age	±SD	(yrs)	 69.6	±17.6	 68.9	±18.5	 70.3	±16.4	 P<0.001	 74.1	±14.1	 69.8	±16.9	 69.8	±17.4	 P<0.001	
Males,	n	(%)	 22933	(45.4)	 11527	(42.8)	 11406	(48.2)	 P<0.001	 3337	(45.8)*	 2818	(49.6)	 2748	(48.5)	 *P=0.002	vs.	AE&IP	
Pre	existing	CKD,	n	(%)	 17212	(34.2)	 8303	(30.9)	 8909	(37.9)	 P<0.001	 3405	(46.9)	 1766	(31.2)	 1904	(33.6)	 P<0.001	for	all	
AKI	stage	1,	n	(%)	 37424	(74.0)	 19686	(73.2)	 17738	(75.0)	 P<0.001	AKI1	
vs.	AKI2/3	
5499	(75.5)	*#	 4157	(73.2)#	 4468	(78.8)	 AKI1	vs.	AKI2/3	
*P=0.003	vs.	IP	
#P<0.001	vs.	AE	
AKI	stage	2,	n	(%)	 8020	(15.9)	 4429	(16.5)	 3591	(15.2)	 1113	(15.3)	 980	(17.3)	 807	(14.2)	
AKI	stage	3,	n	(%)	 5116	(10.1)	 2787	(10.4)	 2329	(9.8)	 673	(9.2)	 540	(9.5)	 392	(6.9)	
Admission	to	ICU,	n	(%)	 2600	(5.1)	 1308	(4.9)	 1292	(5.5)	 P=0.002	 337	(4.6)	 384	(6.8)	 341	(6.0)	 n/s	
Progression	of	AKI,	n	(%)	 5734	(11.3)	 2633	(9.8)	 3101	(13.1)	 P<0.001	 986	(13.5)*	 756	(13.3)*	 678	(12.0)	 P=0.02	vs.	A&E	
90	day	mortality,	n	(%)	 11285	(22.6)	 4947	(18.5)	 6338	(27.2)	 P<0.001	 1953	(26.9)	 1744	(30.9)*	 1505	(26.8)	 *P<0.001	
Baseline	eGFR	data	were	missing	for	198	episodes	(69,	No	recent	test;	129,	Recent	test;	18,	PC;	8,	IP;	5,	A&E)	and	excluded	from	analysis	of	the	Pre-existing	CKD	variable.	Mortality	data	
was	available	for	50022	episodes	(26715,	No	recent	test;	23307,	Recent	test;	7262,	PC;	5643,	IP;	5609,	A&E).	CA-AKI,	Community	acquired	AKI;	PeCKD,	Pre-existing	chronic	kidney	
disease;	ICU,	Intensive	Care	Unit;	PC,	Primary	Care;	IP,	Inpatient;	A&E,	Accident	and	Emergency.	
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Table	2:	Clinical	location	of	blood	test	taken	prior	to	and	within	30	days	of	incident	AKI	episode.		
	 	 	 	
Clinical	location	of	previous	test	
Number	of	CA-
AKI	episodes	
%	of	all	CA-AKI	
episodes	
Mean	time	from	
previous	test	to	
AKI	episode	±SD	
(days)	
No	recent	test	 26902	 53.2	 -	
GP	Practice	 7285	 14.4	 13.3	±9.7	
Inpatient	 5677	 11.2	 10.7	±9.6	
Accident	&	Emergency	 5667	 11.2	 7.3	±8.8	
Out	Patient	 2512	 5.0	 13.5	±9.6	
Day	Case	 1240	 2.5	 10.4	±8.6	
Other*	 1099	 2.2	 9.6	±9.7	
Private	Patient	 98	 0.2	 8.2	±8.1	
Research	and	Development	 42	 0.1	 6.9	±8.0	
Ante-natal	 38	 0.1	 14.2	±11.0	
Total	 26902	 100.0	 10.9	±9.7	
*Other	included	the	following	patient	types:	Other,	Renal,	Renal	and	Transplant,	Renal	Dialysis,	
Community,	Genito-Urinary	Medicine,	Family	Planning,	Environmental,	Home	Office,	and	
Occupational	Health.	
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Table	3:	Clinical	location	of	AKI	alert.		
	 	 	 	 	 ‘Recent	test’	cohort	
Clinical	location	of	AKI	alert,	n	(%)	
All		
CA-AKI	
No	recent	
test	 Recent	test	
P	value	
(Recent	test	
vs.	No	recent	
test)	
Previous	test	
in	primary	
care	
Previous	test	
as	an	
inpatient	
Previous	test	
at	A&E	
P	value	
(‘Recent	test’	
groups)	
Accident	&	Emergency	 26149	(51.7)	 12980	(48.3)	 13169	(55.7)	 P<0.001	 3488	(26.5)	 3417	(25.9)	 4592	(34.9)	 P<0.001	for	all	
GP	Practice	 15905	(31.5)	 10334	(38.4)	 5571	(23.6)	 P<0.001	 3144	(56.4)	 1092	(19.6)	 583	(10.5)	 P<0.001	for	all	
Out	Patient	 5224	(10.3)	 2729	(10.1)	 2495	(10.6)	 n/s	 439	(17.6)	 617	(24.7)	 255	(10.2)	 P<0.001	for	all	
Day	Case	 1716	(3.4)	 342	(1.3)	 1374	(5.8)	 P<0.001	 100	(7.3)	 290	(21.1)	 123	(9.0)	 P<0.001	for	all	
Other*	 1306	(2.6)	 437	(1.6)	 869	(3.7)	 -	 107	(12.3)	 228	(26.2)	 100	(11.5)	 -	
Private	Patient	 148	(0.3)	 47	(0.8)	 101	(0.4)	 P<0.001	 3	(3.0)	 23	(22.8)	 6	(5.9)	 -	
Ante-natal	 68	(0.1)	 21	(0.1)	 47	(0.2)	 P<0.001	 3	(6.4)	 7	(14.9)	 1	(2.1)	 -	
Research	and	Development	 44	(0.1)	 12	(0.04)	 32	(0.1)	 P<0.001	 1	(3.1)	 3	(9.4)	 7	(21.9)	 -	
Total	 50560	 26902	 23658	 -	 7285	 5677	 5667	 -	
*Other	included	the	following	patient	types:	Other,	Renal,	Renal	and	Transplant,	Renal	Dialysis,	Community,	Genito-Urinary	Medicine,	Family	Planning,	Environmental,	
Home	Office,	and	Occupational	Health.	
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Table	4:	Clinical	location	of	blood	test	following	the	incident	AKI	alert.		
	 	 	 	 	 ‘Recent	test’	cohort	
Clinical	location	of	repeat	test,	n	(%)	mean	time	to	
repeat	test	±SD	(days)	
All		
CA-AKI	 No	recent	test	 Recent	test	
P	value	
(Recent	test	vs.	
No	recent	test)	
Previous	test	in	
primary	care	
Previous	test	as	
an	inpatient	or	
at	A&E	
P	value	(‘Recent	
test’	groups)	
Inpatient	 16579	(32.8)	 8032	(29.9)	 8547	(36.1)	 P<0.001	 2309	(27.0)	 4905	(57.4)	 P<0.001	
2.7	±7.1	 3.1	±8.3	 2.3	±5.7	 P<0.001	 2.2	±5.5	 2.2	±5.5	 n/s	
GP	Practice	 10396	(20.6)	 6503	(24.2)	 3893	(16.5)	 P<0.001	 2199	(56.5)	 1182	(30.4)	 P<0.001	
15.9	±18.1	 17.6	±19.3	 13.1	±15.5	 P<0.001	 12.4	±14.2	 13.9	±17.4	 P=0.007	
Accident	&	Emergency	
	
9998	(19.8)	 4955	(18.4)	 5043	(21.3)	 P<0.001	 1408	(27.9)	 2947	(58.4)	 P<0.001	
6.4	±14.3	 7.5	±16.5	 5.4	±11.8	 P<0.001	 4.3	±11.5	 6.0	±12.1	 P<0.001	
No	repeat	test	
	
7923	(15.7)	 5306	(19.7)	 2617	(11.1)	 P<0.001	 853	(32.6)	 1348	(51.5)	 n/s	
-	 -	 -	 -	 -	 -	 -	
Out	Patient	 2788	(5.5)	 1245	(4.6)	 1543	(6.5)	 P<0.001	 266	(17.2)	 470	(30.5)	 n/s	
19.7	±21.2	 26.8	±23.7	 14.0	±16.9	 P<0.001	 21.3	±21.9	 13.1	±17.6	 P<0.001	
Other*	 1431	(2.8)	 522	(1.9)	 909	(3.8)	 P<0.001	 169	(18.6)	 211	(23.2)	 -	
9.8	±15.9	 12.8	±19.4	 8.1	±13.2	 P<0.001	 7.6	±13.7	 6.2	±12.3	 n/s	
Day	Case	 1291	(2.6)	 288	(1.1)	 1003	(4.2)	 P<0.001	 76	(7.6)	 260	(25.9)	 P<0.001	
9.6	±12.4	 15.2	±17.3	 8.1	±10.1	 P<0.001	 7.6	±11.0	 7.6	±13.0	 n/s	
Private	Patient	 87	(0.2)	 33	(0.1)	 54	(0.2)	 P<0.001	 2	(3.7)	 7	(13.0)	 n/s	
7.9	±15.7	 12.8	±19.9	 5.1	±12.1	 P=0.034	 10.4	±14.7	 5.7	±8.0	 n/s	
Research	and	Development	 37	(0.1)	 7	(0.03)	 30	(0.1)	 P<0.001	 -	 6	(20.0)	 -	
3.4	±8.6	 8.6	±18.2	 2.3	±4.1	 n/s	 -	 2.0	±2.8	 -	
Ante-natal	 30	(0.1)	 11	(0.04)	 19	(0.1)	 P<0.001	 3	(15.8)	 8	(42.1)	 n/s	
8.9	±16.2	 17.3	±25.0	 4.1	±3.2	 P=0.030	 3.5	±2.0	 4.5	±3.8	 n/s	
Total	 50560	 26902	 23658	 -	 7285	 11344	 -	
8.3	±15.0	 10.2	±17.3	 6.4	±12.0	 P<0.001	 7.1	±12.7	 5.4	±11.5	 P<0.001	
*Other	included	the	following	patient	types:	Other,	Renal,	Renal	and	Transplant,	Renal	Dialysis,	Community,	Genito-Urinary	Medicine,	Family	Planning,	Environmental,	Home	Office,	and	
Occupational	Health.	
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